Muriel Quaranta Selected Research

cdc25 Phosphatases

3/2009	IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells.
10/2008	Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties.
9/2005	Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases.
1/2003	Inhibitors of the CDC25 phosphatases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Muriel Quaranta Research Topics

Disease

9	Neoplasms (Cancer) 01/2018 - 01/2003
2	Colonic Neoplasms (Colon Cancer) 01/2016 - 04/2014
1	Carcinogenesis 01/2021
1	Juvenile polyposis syndrome 02/2019
1	Inflammation (Inflammations) 01/2018
1	Hemorrhage 01/2018
1	Starvation 01/2016
1	Osteosarcoma (Osteogenic Sarcoma) 01/2014
1	Alzheimer Disease (Alzheimer's Disease) 01/2003

Drug/Important Bio-Agent (IBA)

4	cdc25 PhosphatasesIBA 03/2009 - 01/2003
2	EnzymesIBA 04/2014 - 09/2005
1	Virulence Factors (Pathogenicity Factors)IBA 01/2021
1	Sirolimus (Rapamycin)FDA Link 02/2019
1	Thrombin FDA Link 01/2018
1	Glycogen Synthase (Synthase I)IBA 01/2016
1	Caspase 3 (Caspase-3)IBA 01/2016
1	ChromatinIBA 04/2014
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 01/2014
1	DNA (Deoxyribonucleic Acid)IBA 01/2014
1	quinone (benzoquinone)IBA 03/2009
1	2- (2,5- difluorophenyl)- 6- ((3- (methyl(3- ((2- methyl- 4,7- dioxo- 4,7- dihydro- 1,3- benzothiazol- 5- yl)amino)propyl)amino)propyl)amino)- 1,3- benzoxazole- 4,7- dioneIBA 03/2009
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 06/2006
1	BN 82685IBA 09/2005
1	Protein Isoforms (Isoforms)IBA 08/2005
1	Dual-Specificity PhosphatasesIBA 08/2005
1	BN82002IBA 05/2004

Therapy/Procedure

2	Therapeutics 03/2009 - 10/2008